Raymond Douglas, MD
Ophthalmology · Beverly Hills, CANPI 1124041959
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.9%), grants and speaking fees — rather than concentrated in one kind of arrangement. Amgen accounts for 98.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $371,595 and has fallen 99.4% since, to $2,286 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $4337.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.2M
- Vertical Pharmaceuticals, LLC$15K
- Kedrion Biopharma, Inc.$2K
- AbbVie$311
- Genentech USA, Inc.$144
- Galderma Laboratories, L.p.$143
- plus $84 from 2 others
Across 34 payments — averaging $249,331 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$8.5M
What the payments were for
- Consulting fees$480,13538%
- Speaking & faculty fees$270,82321%
- Grants$465,95237%
- Travel & lodging$44,6344%
- Food & beverage$5,0760%
- Education$00%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 275 | $1,248,634 |
| Vertical Pharmaceuticals, LLC | 2 | $15,050 |
| Kedrion Biopharma, Inc. | 8 | $2,253 |
| AbbVie | 3 | $311 |
| Genentech USA, Inc. | 1 | $144 |
| Galderma Laboratories, L.p. | 1 | $143 |
| Stryker | 1 | $84 |
| Travere Therapeutics, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,097,946
- KRYSTEXXA$27,300
- Albuked$2,172
- KOATE$2,172
- GAMMAKED$2,172
- KEDRAB$2,172
- RhoGAM Ultra-Filtered PLUS$2,172
- VUITY$148
- Erivedge$144
- BOTOX COSMETIC$141
How this compares
$1,266,620 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Beverly Hills
- Stuart StollBeverly Hills$673K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.